MultiCell Technologies Inc (MCET)

[Mcetdreamer]

1) MultiCell owns patents on T-cells and Toll-receptors

Multicell Technology announced that MCTI has acquired certain intellectual property and other assets, including laboratory equipment and key employees of Astral, a San Diego The IP being acquired includes 120 US and 20 foreign issued and pending patents and patent applications related to chimeric antibody technology, treatment of type 1 diabetes, T-cell tolerance, Toll-like receptor technology, dendritic cells, dsRNA technology and immunosuppression.

Clink here to read article:

https://www.thepharmaletter.com/article/multicell-forms-new-company

Article:

MultiCell forms new company
18-09-2005

MultiCell Technologies, a US adult stem-cell company and a supplier of immortalized non-tumorigenic human hepatocytes for drug discovery applications, announced that it has formed a new company, MultiCell Immunotherapeutics, which will be a majority-owned subsidiary of MCET that will develop new therapeutic products utilizing stem cells and other related technologies.

In connection with these efforts, MultiCell announced that MCTI has acquired certain intellectual property and other assets, including laboratory equipment and key employees of Astral, a San Diego, USA-based biotechnology firm developing novel therapies for the treatment of type 1 diabetes, multiple sclerosis, cancer and infectious disease. The IP being acquired includes 120 US and 20 foreign issued and pending patents and patent applications related to chimeric antibody technology, treatment of type 1 diabetes, T-cell tolerance, Toll-like receptor technology, dendritic cells, dsRNA technology and immunosuppression.


4)
MultiCell Technologies Inc Announces Positive Preclinical Results For MCT-465 And MCT-485 In Primary Liver Cancer In Vitro Models
MultiCell Technologies Inc announced that representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012. MCT-465 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of patented TLR3 signaling technology. MCT-465 and MCT 485 are in preclinical development, and are being investigated as prospective treatments for primary liver cancer and triple negative breast cancer. MCT-465 is a high molecular weight synthetic dsRNA (polyA:polyU, of 70bps) with immune enhancing properties. The mechanism of action of MCT-465 is pleiotropic and mediated by RNA sensors – such as TLR3, 7/8, MDA-5 and RIG-I - expressed by antigen presenting cells and select cases, by tumor cells. Prior studies with similar compounds support immune enhancing effect of MCT-465, consisting in generation of Tc immunity against tumors, when administered as a companion to a vaccine. This raises the possibility that MCT-465 is an effective adjunctive therapy to any small molecule targeted therapy (such as tyrosine kinase inhibitors - TKIs) that results in release of endogenous tumor antigen while interfering minimally with the immune competence.MCT-485 is a low molecular weight synthetic dsRNA (polyA:polyU of 5bps) with direct tumor cytolytic properties. The mechanism of action of MCT-485 is pleiotropic yet distinct from that of MCT-465.

9 years ago

I am sorry I don't have time, to find this information.

But I was looking for MCETs Patents I believe it has the words "TLR3 signaling technology"

It also mentioned in
MCET'S 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Click here to see link:

https://seekingalpha.com/filing/2316858


2)

Multicell Technology Inc Adrian Bot

Patent link:
https://patents.google.com/patent/US8809290B2/en

Multicell Technology Inc Patent:

US8809290B2
United States

Patent
Inventor Adrian Bot Lilin WangDan Joseph SmithWilliam Joseph Phillips, Jr.Luis A. DellamaryCurrent Assignee Multicell Immunotherapeutics Inc
Worldwide applications
2003 EP EP AU CA AT DE JP US CN WO 2011 US
Application US13/078,119 events
2002-09-20
Priority to US41221902P
2011-04-01
Application filed by Multicell Immunotherapeutics Inc
2011-11-10
Publication of US20110274705A1
2014-08-19
Application granted
2014-08-19
Publication of US8809290B2
Status
Expired - Fee Related
2024-10-01
Adjusted expiration